EHA 2025 | The potential impact of the ICAHT grading tool
In this video, Kai Rejeski, MD, Ludwig Maximilian University of Munich, Munich, Germany, comments on the potential value and impact of the immune effector cell-associated hematotoxicity (ICAHT) standardized grading system, highlighting that this tool and the associated severity-based treatment recommendations should help to reduce the overall toxicity burden of CAR T-cell therapy. Additionally, the implementation of the tool in clinical trials will allow for the evaluation of safety signals between CAR products. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So we’re already seeing this management or this grading system implemented both in registries and also in clinical trials, which will help comparability of CAR T-cell related hematological toxicity across diseases, across CAR T-cell products. So we think that that’s a real advance because it allows us to evaluate safety signals with one CAR product versus another...
So we’re already seeing this management or this grading system implemented both in registries and also in clinical trials, which will help comparability of CAR T-cell related hematological toxicity across diseases, across CAR T-cell products. So we think that that’s a real advance because it allows us to evaluate safety signals with one CAR product versus another.
In terms of management, we’ve made recommendations for severity-derived management recommendations, and these now allow us to basically say, if you have grade 1 toxicity, do this. If you have grade 3 toxicity, do this. I think that’s an advance because it allows us to standardize management. And with other CAR T-cell toxicities such as CRS, such as ICANS, we’ve seen that this definition of severity grades and then the development of severity-based treatment recommendations really set the stage for reducing the overall toxicity burden. And that’s our hope, that we can make these similar gains also for hematologic toxicity.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
